BRCA1 Antibody (6B4)

Chromatin Immunoprecipitation: BRCA1 Antibody (6B4) [NB100-404] - The 6B4 and 17F8 mixture (3 microgram each), or normal mouse IgG (6 microgram) were incubated with HeLa chromatin extract (100 microgram each) in the ChIP assay. Enrichment of genomic DNA on a BRCA1 target gene promoter (HMGA2) was validated by a Q-PCR assay.

Western Blot: BRCA1 Antibody (6B4) [NB100-404]

Western Blot: BRCA1 Antibody (6B4) [NB100-404] - Non-transfected (-) and transfected (+) 293T whole cell extracts (60 ug) were separated by 5% SDS-PAGE, and the membrane was blotted with BRCA1 antibody [6B4] - ChIP grade diluted at 1:500.

Western Blot: BRCA1 Antibody (6B4) [NB100-404]

Western Blot: BRCA1 Antibody (6B4) [NB100-404] - NB100-404 was used at 1:1000 dilution for Western blot assay of lysates from cells transfected with control or BRCA1-specific siRNA. Lysates were prepared at the indicated times following transfection. RAD50 antibody (13B3) (NB100-147) was used as a loading control.

Immunoprecipitation: BRCA1 Antibody (6B4) [NB100-404]

Immunoprecipitation: BRCA1 Antibody (6B4) [NB100-404] - 6B4 alone (4 microgram), 17F8 alone (4 microgram), 6B4 plus 17F8 (2 microgram each), and mouse control normal IgG were used in an immunoprecipitation assay with MCF7 cell extract. Immunoprecipitated BRCA1 was detected in WB using BRCA1 antibody 6B4 at 1:1000 dilution. HeLa whole cell extract (20 microgram) was used as input in the Western blot assay.

Western Blot: BRCA1 Antibody (6B4) [NB100-404]

Western Blot: BRCA1 Antibody (6B4) [NB100-404] - DAG-induced DNA damage is repaired by homologous recombination. A549 cells were transfected with either negative control (C) or three BRCA1-targeting siRNAs (B1, siBRCA1-2; B2, siBRCA1-15; or B3, siBRCA1-17) for 24 h. Cells were then seeded in 96-well culture plates and treated with different concentrations of VAL-083 (0, 100 nM, 500 nM, 1 uM, 1.5 uM, 2.5 uM, 5 uM, 10 uM, 25 uM, 50 uM, 100 uM, and 200 uM) for 5 days. Following the treatment, crystal violet assay was performed to detect the absorbance at 560 nm wavelength. Cell lysates from the control or BRCA1-knockdown cells were analyzed by western blot with antibody against BRCA1, and GAPDH was used as a loading control. Image collected and cropped by CiteAb from the following publication (https://www.nature.com/articles/s41419-018-1069-9) licensed under a CC-BY license.

Western Blot: BRCA1 Antibody (6B4) [NB100-404] -

Western Blot: BRCA1 Antibody (6B4) [NB100-404] - Wild-type (WT) and BRCA1 knockout (KO) HeLa cell extracts (30 ug) were separated by 5% SDS-PAGE, and the membrane was blotted with BRCA1 antibody, diluted at 1:500. A HRP-conjugated anti-mouse IgG antibody was used to detect the primary antibody, and the signal was developed with Trident ECL plus-Enhanced.

Western Blot: BRCA1 Antibody (6B4) [NB100-404] -

Western Blot: BRCA1 Antibody (6B4) [NB100-404] - Various whole cell extracts (30 ug) were separated by 5% SDS-PAGE, and the membrane was blotted with BRCA1 antibody [6B4] - ChIP grade (NB100-404) diluted at 1:500. The HRP-conjugated anti-mouse IgG antibody was used to detect the primary antibody, and the signal was developed with Trident femto Western HRP Substrate.